On election day, Tuesday, November 5, Americans will choose between former President Donald Trump and current Vice President ...

Morgan Stanley lowered the firm’s price target on Zenas BioPharma (ZBIO) to $35 from $40 and keeps an Overweight rating on the shares. The firm ...

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Zenas BioPharma, Inc. (ZBIO – Research Report), with ...

Biopharma leaders at companies developing blood cancer therapies say we shouldn’t be afraid to use the four-letter word: cure ...

The phase 3 clinical trial of CAN-2409 in intermediate-to-high-risk, localized prostate cancer met its primary endpoint, by demonstrating statistically significant improvement in disease-free survival ...

Cybin (OTCMKTS:CYBN – Get Free Report) and 9 Meters Biopharma (NASDAQ:NMTR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two ...

A new report commissioned by life sciences leader Cytiva sheds light on the sustainability landscape in biopharma. Drawing ...

Benitec Biopharma Inc. (NASDAQ:BNTC – Get Free Report) has earned an average rating of “Buy” from the six analysts that are ...

("Quantum BioPharma") provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu" or the "Company"), and its launching of unbuzzd™, an innovative beverage product ...

BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet ...

GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share. The shares will be ...